Hit enter to search or ESC to close
personalized medicine took
a giant leap forward
came to market sooner
we could halt
Neuron23™ is a dynamic biotechnology company, uniquely positioned to develop personalized medicines for genetic disorders.
Neuron23™ Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group
© 2022 Neuron23. All Rights Reserved